NTRK1 and hematologic disorder: The success of early clinical trials with larotrectinib and entrectinib as well as the different studies discussed above suggest that oncogenic Trk aberrations are amenable to targeted inhibition and hold the promise of providing clinical benefit in a variety of hematologic malignancies.